fulvestrant,lasofoxifene
sermonix,pfizer
[' fulv', 'lasofoxifene']
 exactly the population studied in our small signal-seeking elaine 1 phase 2 study of serm lasofoxifene v fulvestrant presented at esmo today. all 103 patients post-ai/cdk and esr1 mut+. while not stat sig, mpfs of 6 v 4 mos, orr 13% v 3% cbr 37% v 22% all favored lasofoxifene
CEO, Chief Medical Officer, Sermonix: clinical & research interest in breast cancer, menopause, osteoporosis, and sexual health